Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palatability of sisunatovir oral suspension
NCT06003829Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2023
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of sisunatovir in respiratory syncytial virus infection (RSV) (6 arms), sponsored by Pfizer. Primary endpoint: Mean Score of Sensory Attributes Based on Palatability Assessment Questionnaire. Started Jul 2023; status: completed.
02
Drugs
sisunatovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06003829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06003829.